| Sogroya® (somapacitan injection) now available in Canada as the first and only once-weekly treatment for both children and adults living with growth hormone deficiency | 2025.10.15 |
| Novo Nordisk Canada and Pocketpills Announce Collaboration to Provide Enhanced Online Pharmacy and Prescription Services and Support for Ozempic® and Wegovy® | 2025.09.18 |
| Health Canada approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease | 2025.08.19 |
| CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM | 2025.06.24 |
| Higher dose of semaglutide provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA | 2025.06.23 |
| Health Canada accepts semaglutide 2.4 mg, a GLP-1RA treatment for MASH, as a supplemental New Drug Submission under the Priority Review Policy | 2025.05.02 |
| Camp Huronda infographic | 2021.01.14 |